FL

Fulgent Genetics IncNASDAQ FLGT Stock Report

Last reporting period 30 Jun, 2024

Updated 04 Nov, 2024

Last price

Market cap $B

0.649

Micro

Exchange

XNAS - Nasdaq

FLGT Stock Analysis

FL

Uncovered

Fulgent Genetics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

23/100

Low score

Market cap $B

0.649

Dividend yield

Shares outstanding

29.519 B

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in Temple City, California and currently employs 1,012 full-time employees. The company went IPO on 2016-09-28. The firm develops a technology platform, which offers a test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels. Its test offerings also include Solid Tumor Molecular Profiling for somatic cancer testing, Rapid Whole Genome testing developed for children in neonatal intensive care units or pediatric intensive care units its Newborn Genetic Analysis panel, and a single front-line test designed to comprehensively detect ataxia-related variants. The company also offers certain research service tests, which are ordered by research institutions and other similar institutional customers.

View Section: Eyestock Rating